OHSU study uncovers internal cell ‘trade winds’ that drive movement and repair

Oregon Health & Science University scientists capture a 3D single-molecule super-resolution microscopy image showing individual actin protein molecules inside a cell, each rendered as a single dot and captured at extraordinary detail — roughly 10,000 times finer than a human hair. Colors indicate depth within the cell, from blue at the bottom to magenta at the top. The blue and magenta dots cluster into curved structures that form a wall-like barrier separating the region of active fluid flow from the rest of the cell interior.
Image Credit: OHSU/Christine Torres Hicks

Scientific Frontline: Extended "At a Glance" Summary: Directed Cellular Fluid Flows ("Trade Winds")

The Core Concept: Cells utilize actively directed, targeted streams of fluid—comparable to internal "trade winds" or atmospheric rivers—to rapidly transport essential soluble proteins to their leading edge to facilitate movement, adhesion, and repair.

Key Distinction/Mechanism: For decades, traditional biological models proposed that free-floating proteins moved inside cells primarily via random diffusion. This discovery reveals that cells instead actively "squeeze" at their rear, generating nonspecific fluid currents that propel proteins, such as soluble actin, forward much faster than diffusion. These flows are channeled into a specialized front compartment separated by an actin-myosin condensate barrier, which acts as a physical wall to target the material exactly where it is needed.

Major Frameworks/Components: 

• Targeted Fluid Currents: Nonspecific internal cellular flows that rapidly sweep multiple types of proteins toward advancing regions of the cell edge.
• Actin-Myosin Condensate Barrier: A physical, intracellular wall that separates the cell's specialized front compartment from the rest of the cell to direct the fluid flow.
• Pseudo-Organelle: A newly identified functional cellular compartment that lacks a traditional membrane but physically organizes and dictates cellular behavior.
• FLOP (Fluorescence Leaving the Original Point): An inverse fluorescence microscopy technique developed by the research team to visualize and track these previously unseen cellular currents.
• Interferometric Photoactivated Localization Microscopy (iPALM): Advanced 3D super-resolution imaging utilized to resolve the nanometer-scale structures of these cellular compartments.

Immunotherapy significantly improves outcomes for colon cancer

Anke Reinacher-Schick was involved in the study.
Photo Credit: © Jakob Studnar

Scientific Frontline: Extended "At a Glance" Summary: Immunotherapy for Stage III Colon Cancer

The Core Concept: A highly effective clinical protocol that combines the immunotherapy atezolizumab (Tecentriq®) with standard adjuvant FOLFOX chemotherapy to treat patients with resected stage III colon cancer exhibiting deficient DNA mismatch repair (dMMR).

Key Distinction/Mechanism: Unlike conventional treatments that rely solely on cytotoxic mechanisms, this protocol integrates immunotherapy to target a biologically distinct, early-stage cancer subgroup. The addition of atezolizumab bolsters the immune system's response to dMMR tumors, resulting in a 50 percent reduction in the risk of disease recurrence or death compared to standard chemotherapy alone.

Major Frameworks/Components:

• Atezolizumab (Tecentriq®): The primary immunotherapeutic agent utilized to enhance the immune response.
• FOLFOX Chemotherapy: The established adjuvant chemotherapy regimen used as the baseline therapeutic foundation.
• Deficient DNA Mismatch Repair (dMMR): The specific genetic and biological biomarker identifying the patient subgroup eligible for this combined therapy.
• Phase III Alliance ATOMIC A021502 Trial: The global, multi-institutional clinical trial that verified the efficacy of the treatment protocol.

How inflammation may prime the gut for cancer

An image of mouse colon during chronic colitis displays the effects of inflammation, which can lead to lasting changes in the epigenome that promote cancer.
Image Credit: Courtesy of the Buenrostro Lab 

Scientific Frontline: Extended "At a Glance" Summary: Epigenetic Priming of Colorectal Cancer

The Core Concept: Chronic intestinal inflammation leaves lasting molecular scars, or epigenetic "memories," on seemingly healed gut tissues, fundamentally priming these healthy-appearing cells for future cancer development.

Key Distinction/Mechanism: Unlike traditional models that attribute tumorigenesis solely to the gradual accumulation of genetic mutations, this discovery highlights a structural "one-two punch" mechanism. Prior bouts of inflammation alter the cell's epigenome by keeping specific cancer-associated DNA sites open and accessible. If a subsequent oncogenic mutation occurs later in life, the cell exploits these pre-opened genomic regions to rapidly activate cancer-driving genes and accelerate tumor growth.

Major Frameworks/Components:

• Multiplexed Single-Cell Profiling: An advanced analytical method developed to simultaneously measure individual cells' transcriptional states (active gene expression), epigenomic states (chromatin accessibility), and clonal histories (cellular family trees).
• Epigenetic Memory Persistence: The biological phenomenon where specific chromatin regions remain physically accessible despite the cessation of active inflammation and the return of normal gene expression.
• Stem Cell Inheritance: The mechanism by which strong epigenetic alterations are passed from intestinal stem cells to their descendant "daughter" cells across multiple generations of cell division, creating entire lineages primed for malignancy.
• The "One-Two Punch" Model: The synergistic requirement of both an initial environmental/epigenetic alteration and a later genetic mutation to rapidly drive cancer progression.

The underestimated thymus: New studies reveal its relevance for healthy aging

Thymus health may differ: CT scan of a more healthy (left) and less healthy (right) thymus.
Photo Credit: Bernatz et al., Nature (2026

Scientific Frontline: Extended "At a Glance" Summary: Thymus Health and Immune Aging

The Core Concept: The thymus gland, historically categorized as a predominantly active organ during childhood, remains a vital biological regulator in adulthood, with its health directly correlating to longevity, disease resistance, and immune stability.

Key Distinction/Mechanism: While it is established that the thymus shrinks and undergoes fatty degeneration over a lifespan, recent findings demonstrate that lower levels of fat infiltration—detectable via routine computed tomography (CT) imaging—indicate superior immune function. Unlike localized tumor-based biomarkers, thymus health reflects systemic immune performance, marked by a greater diversity of T-cell receptors and an inherently stronger systemic immune response.

Major Frameworks/Components: 

• Predictor of Longevity and Disease: Optimal thymus health is associated with significantly lower overall mortality, reduced lung cancer incidence, and decreased cardiovascular mortality.
• Immunotherapy Efficacy: Thymic health accurately predicts the success of modern immune checkpoint inhibitors across various cancers (including lung, melanoma, breast, and kidney), independent of established biomarkers like PD-L1 or tumor mutational burden (TMB).
• Diagnostic Imaging Integration: Routine CT scans can objectively measure the degree of thymic fatty degeneration, providing a quantifiable metric for immune aging without requiring invasive procedures.
• Modifiable Health Factor: Thymus function is closely linked to lifestyle factors, indicating that a healthy lifestyle can preserve thymic health and, by extension, overall systemic immunity.

The influence of lymph node architecture on lymphoma

Professor Dr Sascha Dietrich (Director of the Department of Hematology, Oncology and Clinical Immunology) emphasises that the targeted modulation of stromal cells offers great therapeutic potential for the treatment of malignant lymphomas.
Photo Credit: © UKD

Scientific Frontline: Extended "At a Glance" Summary: The Influence of Lymph Node Architecture on Lymphoma

The Core Concept: Stromal cells function as the "architects" of lymph nodes by directing immune cells via chemical signals, but during the development of B cell lymphomas, inflammatory feedback loops reprogram these cells, actively destroying the lymph node's structural organization.

Key Distinction/Mechanism: Unlike the passive displacement of tissue by tumor growth, the structural breakdown in aggressive lymphomas (such as diffuse large B cell lymphoma) is an active process. T cell-produced interferons force stromal cells to replace structure-defining chemokines with inflammatory ones, attracting more inflammatory cells and obliterating the spatial boundaries that remain largely intact in slower-growing lymphomas (such as follicular lymphoma).

Major Frameworks/Components:

• Stromal Cell Regulation: Non-haematopoietic structural cells that normally release chemokines to organize B cells and T cells into specific zones.
• Inflammatory Feedback Loop: The active mechanism where T cells produce interferons in the tumor microenvironment, fundamentally altering stromal chemokine production.
• Advanced Tissue Mapping: The utilization of single-cell analyses and spatial tissue mapping to trace the progressive loss of regulatory signals.

Copper Overload Kills Cancer Cells

Johannes Karges is researching compounds that kill tumor cells.
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Light-Activated Cuproptosis in Cancer Treatment

The Core Concept: Cuproptosis is a specific form of cell death triggered by an excess of intracellular copper. Utilizing this mechanism, researchers have developed a light-activated, copper-based agent complex embedded in polymeric nanoparticles that selectively targets and destroys cancer cells while preserving healthy tissue.

Key Distinction/Mechanism: Unlike conventional apoptosis pathways targeted by standard chemotherapy, cuproptosis is triggered when excess copper binds to mitochondrial proteins responsible for energy production, causing them to clump and inducing fatal cellular stress. To prevent damage to healthy cells, the highly toxic copper complex is encapsulated in polymeric nanoparticles that accumulate in tumors; a localized light stimulus is then used to sever a photo-responsive bond, selectively releasing the copper agent exclusively within the malignant tissue.

Major Frameworks/Components: 

• Targeted Metabolic Disruption: Exploits the altered, highly active metabolism of cancer cells, which naturally intake higher levels of copper compared to healthy tissue.
• Polymeric Nanoparticle Encapsulation: A specialized carrier system that safely transports the copper agent complex, preventing premature or uncontrolled release into the bloodstream.
• Photopharmacology and Photoactivated Chemotherapy (PACT): The integration of light-sensitive (photo-responsive) bonds within the basic polymer framework, requiring specific light radiation to dissolve the nanoparticles and achieve localized, highly controlled drug delivery.

Protein modification discovery opens cancer therapy possibilities

Purdue’s W. Andy Tao (front) and his associates have discovered a new type of modification on proteins from cancer-related mutation that holds potential as a therapeutic target. Three members of his group are co- authors of the study published in Nature Chemistry. From left are graduate students Yi-Kai Liu, Zhoujun Luo, and postdoctoral scientist Zheng Zhang.
Photo Credit: Purdue Agricultural Communications / Joshua Clark

Scientific Frontline: "At a Glance" Summary: Protein Modification and Cancer Therapy

• Main Discovery: Researchers identified a novel type of protein modification driven by mutations in the isocitrate dehydrogenase enzyme, which fundamentally alters how kinase enzymes regulate cellular energy and protein function during cancer development.
• Methodology: The research team analyzed normal cells, IDH1 mutant cells, and IDH1 mutant cells treated with anti-cancer drugs using polymer-based metal ion affinity capture to isolate and identify dozens of proteins modified by the metabolite D-2-hydroxyglutarate.
• Key Data: The targeted isocitrate dehydrogenase mutation is prevalent in over 70 percent of specific cancer types, including glioma, acute myeloid leukemia, and rare forms of liver cancer, directly causing an excessive accumulation of D-2-hydroxyglutarate.
• Significance: This study highlights a previously unrecognized chiral-dependent modification where metabolic byproducts exchange chemical signals through phosphorylation crosstalk, exposing a hidden mechanism that fuels tumor progression and metabolic reprogramming in fast-growing cancers.
• Future Application: The identification of these post-translational modifications provides a new framework for precision medicine, enabling the development of targeted therapeutics and advanced diagnostic imaging techniques specifically for cancers driven by isocitrate dehydrogenase mutations.
• Branch of Science: Biochemistry, Oncology, and Molecular Pharmacology.

New discovery reveals hidden driver of deadly brain cancer

Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: CD47-Mediated Glioblastoma Progression

The Core Concept: Researchers have discovered that the protein CD47 plays a direct, internal role in driving the growth, movement, and invasion of glioblastoma cells into healthy brain tissue, operating independently of its previously established function in immune evasion.

Key Distinction/Mechanism: While CD47 was previously recognized solely as an extracellular "don't eat me" signal that helps cancer cells hide from the immune system, its newly identified mechanism is intracellular. CD47 sequesters a protein called ITCH, preventing it from breaking down another key protein, ROBO2. This shielding allows ROBO2 to accumulate and actively drive tumor progression and invasion.

Major Frameworks/Components:

• CD47: A protein found in high abundance at the invasive edges of glioblastoma tumors, directly correlating with poorer patient survival outcomes.
• ROBO2: A downstream partner protein shielded by CD47 that facilitates cancer cell proliferation, migration, and invasion.
• ITCH: A protein responsible for tagging ROBO2 for cellular degradation, whose function is inhibited when sequestered by CD47.
• CD47-ITCH-ROBO2 Pathway: The newly identified molecular chain of events acting as a central regulator of glioblastoma biology.

Local immune coordination in the lung reveals a new layer of defense

Clusters of immune cells in the influenza-infected lung of a mouse. B cells are shown in cyan, T cells in magenta, and green areas indicate regions with low oxygen levels. Oxygen is particularly scarce at the edges of the cell clusters.
Image Credit: University of Basel, Jean De Lima

Scientific Frontline: "At a Glance" Summary: Local Immune Coordination in the Lung

• Main Discovery: Researchers identified a previously unappreciated subtype of helper T cells that migrate to the lungs during infection and produce the protein HIF-1α to orchestrate a localized, coordinated immune defense.
• Methodology: The team utilized advanced imaging techniques to map immune cell positioning in the lungs of influenza-infected mice and employed a specific mouse model to selectively deactivate the HIF-1α molecule at precise moments post-infection.
• Key Data: Deactivating HIF-1α in targeted T cells reduced the release of the signaling molecule IL-21, triggering a collapse of the local immune network and a subsequent decline in lung macrophages, natural killer cells, and antibody-producing B cells.
• Significance: The findings demonstrate that temporary lung immune hubs act as advanced command centers for broad immune protection, establishing a critical layer of localized respiratory defense that operates independently of the initial systemic immune response.
• Future Application: This discovery offers a biological foundation for designing inhalable vaccines to build immune defenses directly at viral entry sites and presents new strategies for tissue-targeted immunotherapies.
• Branch of Science: Immunology, Pulmonology, Virology, Oncology.
• Additional Detail: The coordinated response of HIF-1α driven T cells was also observed in a mouse model of lung cancer, indicating that their localized protective role extends beyond fighting viral infections to actively combating tumor cells.

Newly discovered genetic weakness may help target deadly small cell neuroendocrine cancers

Small cell neuroendocrine prostate cancer model developed by the Witte Laboratory.
Image Credit: Courtesy of Witte Laboratory

Scientific Frontline: Extended "At a Glance" Summary: Synthetic Lethality in Small Cell Neuroendocrine Cancers

The Core Concept: Small cell neuroendocrine cancers, which frequently lack the tumor-suppressing RB gene, exhibit a critical dependency on the E2F3 protein for survival. This dependency creates a vulnerability known as synthetic lethality, where inhibiting E2F3 in RB-deficient cells effectively halts tumor growth and induces cancer cell death.

Key Distinction/Mechanism: Unlike traditional targeted therapies that often fail against these highly aggressive tumors, this approach exploits a dual-gene metabolic dependency. While cancer cells can easily survive and rapidly multiply following the loss of the protective RB gene alone, the simultaneous removal or inhibition of the E2F3 protein collapses the cell's viability. Because no drugs currently target E2F3 directly, researchers suppress it indirectly by blocking the DHODH enzyme, which disrupts the metabolic pathway used to synthesize DNA building blocks.

Origin/History: Published in the Proceedings of the National Academy of Sciences in March 2026, this breakthrough stems from over a decade of research by the Witte Laboratory at UCLA. Researchers successfully developed new laboratory models by genetically altering normal human prostate cells, enabling the use of genome-wide CRISPR screens to pinpoint hidden genetic weaknesses.

Scientists turbocharge immune cells to attack prostate cancer

A graphic illustration showing how the introduction of catch bonds between TCR and pMHC enhances anti-tumor efficacy
Illustration Credit: Witte Lab  

Scientific Frontline: "At a Glance" Summary: Catch Bond Engineered T Cells for Prostate Cancer

• Main Discovery: Researchers engineered a new class of T cells that utilize a mechanical "catch bond" to strengthen their physical interaction with prostate cancer cells, enabling a highly targeted, potent, and sustained immune response.
• Methodology: Scientists altered a single amino acid in a naturally weak T cell receptor (TCR156) designed to detect prostatic acid phosphatase, a common prostate cancer protein. The modified receptors were evaluated using single-cell RNA sequencing, atomic-resolution structural analyses, biomembrane force probes, and in vivo mouse models.
• Key Data: The single amino acid modification delayed or completely halted tumor growth in mouse models, whereas unmodified T cells exhibited little to no effect. The engineered cells also demonstrated prolonged contact with cancer cells and increased secretion of critical tumor-killing molecules, including Granzyme B, IFNγ, and TNFα.
• Significance: This mechanical modification overcomes immune tolerance by allowing T cells to forcefully engage and destroy tumors that express self-antigens, all while strictly preserving precision and avoiding off-target toxicity to healthy tissue.
• Future Application: Catch bond engineering establishes a generalizable structural strategy and predictive framework to develop safer, longer-lasting adoptive T cell therapies for a wide array of solid tumors.
• Branch of Science: Immunology, Oncology, Molecular Biology, Structural Biology.

Researchers develop promising new therapy for most common form of bone cancer in children and young adults

A visual representation of a large, solid osteosarcoma tumor mass (bone cancer, left) being specifically targeted by a swarm of engineered CAR-T cells (right). The T-cells use specialized chimeric antigen receptors (visualized as precise, matching 'locks' in cyan and gold) to lock onto specific 'keys' (the glowing blue Oncostatin M, or OSM, protein receptors) on the surface of the cancer cells. In the center, a single CAR-T cell has successfully engaged, releasing a powerful, radiant energy reaction (golden-orange) that causes the osteosarcoma cell to fracture and lyse, demonstrating the targeted destruction of the solid tumor. A few fragmented cancer cells are shown drifting away, implying the systemic hunt against metastatic spread.
Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: OSM CAR-T Therapy for Osteosarcoma

The Core Concept: OSM CAR-T is a newly engineered immune-cell therapy designed to specifically target and destroy osteosarcoma, the most common form of bone cancer affecting children and young adults.

Key Distinction/Mechanism: While conventional Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized treatment for blood cancers, it traditionally struggles against solid tumors due to complex surface markers. The OSM CAR-T therapy overcomes this limitation by specifically targeting receptors of the Oncostatin M (OSM) protein found on the surface of osteosarcoma cells, enabling the engineered immune cells to identify and attack multiple cancer cell receptors simultaneously.

Major Frameworks/Components:

• Chimeric Antigen Receptor T-cell (CAR-T) Therapy: The foundational technology that reprograms a patient's own immune T-cells to recognize and eliminate malignant cells.
• Oncostatin M (OSM) Protein: The specific surface protein biomarker targeted by the engineered T-cells to effectively breach the solid tumor defenses of osteosarcoma.
• Metastatic Efficacy Models: Preclinical mouse models demonstrating the therapy's capability to hunt and destroy osteosarcoma cells that have spread to secondary organs, a primary challenge in current oncology.

Novel cancer drug delivery system improves Paclitaxel absorption

Paclitaxel binding to L-PGDS
Improved solubility through hydrophobic bonds and CRGDK targeting peptides.
Image Credit: Osaka Metropolitan University

Scientific Frontline: Extended "At a Glance" Summary: Novel Cancer Drug Delivery System for Paclitaxel

The Core Concept: Researchers have developed a targeted drug delivery system (DDS) that utilizes the lipocalin-type prostaglandin D synthase (L-PGDS) enzyme as a carrier to efficiently solubilize and transport Paclitaxel, a heavy and poorly water-soluble anticancer drug, directly to cancerous tissues.

Key Distinction/Mechanism: Unlike conventional formulations that lose their efficacy shortly after administration ceases, this novel system maintains sustained antitumor effects. It functions by binding Paclitaxel via hydrophobic interactions to the β-barrel structure of the L-PGDS protein, which improves the drug's solubility by approximately 3,600-fold. Furthermore, a specialized targeting peptide (CRGDK) is attached to the protein, directing the drug specifically to neuropilin-1 receptors expressed on the surface of cancer cells rather than distributing it to healthy tissues.

Major Frameworks/Components: 

• Paclitaxel (PTX): An established, heavy-molecular-weight (854 Da) anticancer drug traditionally limited by its poor water solubility.
• L-PGDS Enzyme Carrier: The lipocalin-type prostaglandin D synthase protein used as a structural vehicle to house and transport the drug.
• Hydrophobic Interactions: The chemical mechanism allowing PTX to successfully bind to the upper region of the L-PGDS β-barrel.
• CRGDK Targeting Peptide: A specific peptide sequence attached to the C-terminus of L-PGDS that acts as a homing mechanism for neuropilin-1 receptors on cancer cells.

New research reveals why some esophageal cancers are so hard to treat

Esophageal adenocarcinoma section visualised by multiplexed immunofluorescence, showing cell nuclei (greyscale) and micronuclei (aberrant nuclear structures formed when chromosomes are improperly segregated during cell division; red) interspersed throughout the malignant cell compartment (cyan). Infiltrating macrophages are shown in yellow.
Image Credit:  Parkes Lab, Translational Histopathology Laboratory, University of Oxford.

Scientific Frontline: Extended "At a Glance" Summary: Chromosomal Instability in Esophageal Adenocarcinoma

The Core Concept: Highly aggressive esophageal cancers are fundamentally characterized by elevated chromosomal instability, a state where cancer cells continuously make genetic errors during division, thereby accelerating their growth and adaptability.

Key Distinction/Mechanism: Rather than merely driving rapid cellular proliferation, chromosomal instability alters the tumor's interaction with the host immune system. Unstable cancer cells activate specific genes to release chemical signals that attract inflammatory immune cells, effectively hijacking the body's natural defense mechanisms to fortify the tumor and resist medical treatments.

Major Frameworks/Components:

• Chromosomal Instability: The frequent missegregation of chromosomes during cell division, which results in aberrant nuclear structures such as micronuclei scattered throughout the malignant cell compartment.
• cGAS-Chemokine-Myeloid Axis: The specific signaling pathway utilized by chromosomally unstable cells to emit chemical signals and attract supportive inflammatory immune cells (like macrophages) into the tumor.
• Tumor Microenvironment: The local biological environment heavily reshaped by the tumor to support its survival, driven by hijacked immune responses rather than effective immune attacks.

Different pediatric brain tumors originate from the same type of cell

Miao Zhao and Fredrik Swartling have shown that pediatric brain tumors from different parts of the brain share the same biological origin.
Photo Credit: Anjali Sivakumar

Scientific Frontline: Extended "At a Glance" Summary: Common Cellular Origin of Pediatric Brain Tumors

The Core Concept: Severe pediatric brain tumors that develop in entirely distinct anatomical regions—such as the pineal gland, retina, and cerebellum—actually arise from the same type of immature precursor cell containing photoreceptor features.

Key Distinction/Mechanism: While historically tumors like pineoblastoma, retinoblastoma, and medulloblastoma were viewed as biologically independent due to their varied anatomical locations, advanced molecular profiling demonstrates they share a unified origin in light-sensitive precursor cells. This mechanism distinguishes them biologically from other, unassociated tumors developing within those exact same brain regions.

Major Frameworks/Components: 

• Single-Cell Analysis: The use of advanced molecular mapping to profile and compare the biological origins of diverse patient tumors.
• Photoreceptor Signature: The identification of specific proteins associated with light-sensitive cells that are preserved from evolutionary biology and act as drivers for tumor development across distinct central nervous system regions.
• CRISPR/Cas9 Validation: The utilization of genetic scissors in mouse models to block photoreceptor activity, successfully halting tumor growth and confirming the biological target.

Relax study by Dresden scientists: Innovative combination therapy shows promising efficacy in aggressive leukemia

Alongside his colleague Dr. Leo Ruhnke (right side), Prof. Christoph Röllig (left side) designed and supervised the RELAX study
Photo Credit: Courtesy of Dresden University

Scientific Frontline: "At a Glance" Summary: Acute Myeloid Leukemia Combination Therapy

• Main Discovery: The addition of the BCL2 inhibitor venetoclax to intensive chemotherapy substantially improves treatment outcomes for patients suffering from relapsed or refractory acute myeloid leukemia.
• Methodology: Researchers conducted a multicenter phase 1/2 clinical trial known as the RELAX study to evaluate the tolerability and efficacy of combining a standard chemotherapy regimen of cytarabine and mitoxantrone with venetoclax.
• Key Data: The experimental combination therapy achieved a 75 percent complete remission rate, representing a stark increase over the 40 percent remission rate historically observed with conventional chemotherapy alone.
• Significance: By effectively suppressing rapidly growing leukemia cells, this therapeutic approach successfully qualifies a significantly larger proportion of treatment-resistant patients for potentially curative stem cell transplantations.
• Future Application: The treatment regimen is currently undergoing expanded evaluation in over 150 additional patients and demonstrates strong potential to become the new standard of care for treating acute myeloid leukemia relapses.
• Branch of Science: Hematology, Oncology, and Clinical Pharmacology.
• Additional Detail: The therapeutic combination maintained high efficacy even against particularly resistant genetic variants of the disease, with the foundational findings formally published in The Lancet Haematology.

Study finds stress-related nerves may fuel pancreatic cancer growth

Ariana Sattler, Ph.D., right, and Ece Eksi, Ph.D., are co-authors on a new study that found that certain nerves may support pancreatic cancer growth.
Photo Credit: OHSU/Christine Torres Hicks

Scientific Frontline: Extended "At a Glance" Summary: The Role of Sympathetic Nerves in Pancreatic Cancer

The Core Concept: Sympathetic nerves, which regulate the body's "fight or flight" stress response, can infiltrate pancreatic tumors and actively facilitate their growth by communicating with cancer cells and surrounding support cells.

Key Distinction/Mechanism: Traditional oncology has heavily focused on intra-tumor components like immune cells, blood vessels, and fibroblasts while largely overlooking the nervous system, as the main bodies of nerve cells reside outside the tumor. This new paradigm demonstrates that nerves structurally infiltrate the tumor microenvironment and chemically alter the behavior of cancer cells and cancer-associated fibroblasts to promote malignancy.

Major Frameworks/Components: 

• Tumor Microenvironment Integration: Sympathetic nerves act as an external support system, directly embedding into and altering the pancreatic tumor ecosystem.
• Prognostic Genetic Markers: The presence of sympathetic-associated genes correlates with poor survival rates in human patients with pancreatic cancer.
• Sex-Specific Phenotypes: Experimental removal of sympathetic nerves in mouse models resulted in reduced tumor size exclusively in female mice, suggesting that sex hormones heavily influence nerve-tumor communication.

Precision tumor imaging with a fluorescence probe and engineered enzymes

Overview of the probe and enzyme.
A reporter enzyme, engineered by directed evolution, does not bind to healthy tissue, only targeted cancers with particular antigens. A probe is activated by the reporter enzyme which glows under excitation light.
Image Credit: ©2026 Kojima et al. American Chemical Society

Scientific Frontline: "At a Glance" Summary: Precision Tumor Imaging

• Main Discovery: Researchers developed a bioorthogonal fluorescence probe and a matching engineered reporter enzyme that selectively activate at targeted tumor sites, enabling high-contrast tumor visualization with minimal background noise.
• Methodology: The research team used directed evolution to train a reporter enzyme through repeated mutation and selection. In tests utilizing a mouse model with peritoneal cancer, the engineered enzyme was delivered specifically to tumor sites, followed by the introduction of the bioorthogonal dye probe. The probe was designed to remain completely inactive until encountering its matching engineered enzyme.
• Key Data: The targeted bioorthogonal system successfully highlighted millimeter-sized tumor lesions in vivo, demonstrating exceptionally low background fluorescence from surrounding healthy tissues.
• Significance: Conventional fluorescent dyes frequently illuminate healthy tissue via endogenous enzyme activation, complicating surgical tumor excision. This highly selective enzyme-probe pairing effectively eliminates background noise, significantly enhancing surgical precision and minimizing the risk of leaving undetected malignant cells behind.
• Future Application: The system serves as a powerful near-term research tool with significant long-term clinical potential for surgical oncology. Furthermore, by substituting the antigen-targeting component, the same enzyme-probe pairing principles can be adapted to other cancer types for highly targeted drug delivery, ensuring therapeutics exclusively reach malignant sites.
• Branch of Science: Chemical Biology, Molecular Imaging, and Oncology.
• Additional Detail: Before human clinical trials can proceed, researchers must address the significant challenge of ensuring that the engineered reporter enzyme does not provoke an adverse immune response in patients.

Solving cancer immunotherapy’s fuel shortage

Image Credit: Scientific Frontline

Scientific Frontline: "At a Glance" Summary: Cancer Immunotherapy Metabolic Engineering

• Main Discovery: Researchers genetically equipped T cells with fungi-derived proteins, enabling the immune cells to utilize cellobiose—a plant-based sugar that cancer cells cannot metabolize—as an exclusive fuel source to survive and attack solid tumors.
• Methodology: The research team engineered T cells to express two specific proteins that import and convert cellobiose into usable intracellular glucose. These modified cells were first tested in nutrient-depleted laboratory environments simulating solid tumors and subsequently evaluated in vivo using mouse models of solid cancer.
• Key Data: In severe glucose-restricted environments, unmodified T cells rapidly lost function, whereas the engineered T cells maintained viability, continued dividing, and secreted critical cancer-fighting cytokines including IFN-γ and TNF. In mouse models, the administration of these modified T cells resulted in significantly prolonged survival rates, delayed tumor progression, and complete tumor regression in a subset of the test subjects.
• Significance: This metabolic modification resolves a critical limitation in immunotherapy where aggressive solid tumors starve immune cells of ambient glucose. By providing a proprietary nutrient source, the intervention prevents T cell exhaustion and sustains robust anti-tumor immune responses within hostile tumor microenvironments.
• Future Application: This metabolic bypass strategy can be integrated into existing and forthcoming T cell-based treatments, including CAR-T cell therapies, to substantially enhance their clinical efficacy against treatment-resistant solid cancers such as lung, breast, and colorectal tumors.
• Branch of Science: Oncology, Immunology, and Cellular Biology.
• Additional Detail: The alternative fuel source utilized in this study, cellobiose, is a non-toxic sugar naturally found in cellulose that is already recognized as safe by the FDA and routinely used as an additive in everyday consumer food products.

Tiny bubbles, big breakthrough: cracking cancer’s “fortress”

Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Ultrasound-Activated Nanobubbles in Oncology

The Core Concept: Ultrasound-activated inert gas nanobubbles are injected into solid tumors and stimulated with sound waves to mechanically break down the dense, collagen-rich barriers that protect cancer cells, thereby enabling the effective delivery of therapeutic agents.

Key Distinction/Mechanism: Unlike traditional chemical treatments or destructive ablation, this method relies on the gentle mechanical "jiggling" of perfluoropropane-filled nanobubbles via directed ultrasound. This physical agitation remodels and softens the tumor's stiff extracellular matrix without destroying the surrounding cells, uniquely allowing large therapeutic molecules—such as RNA carried in lipid nanoparticles—and endogenous immune cells to penetrate the previously inaccessible tumor core.

Origin/History: The breakthrough was published in ACS Nano by a collaborative team of biomedical engineers and radiologists at Case Western Reserve University, led by Efstathios Karathanasis and Agata Exner, and announced in February 2026. The underlying nanobubble technology is concurrently being commercialized by Visano Theranostics for diagnostic imaging in prostate cancer.